Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice

Human Gene Therapy

Volumn 19, Issue 8, 2008, Pages 795-806

  Sirsi, Shashank R ^a   Schray, Rebecca C ^b   Guan, Xiangying ^b   Lykens, Nicole M ^a   Williams, Jason H ^b   Erney, Michelle L ^b   Lutz, Gordon J ^b  

^a DREXEL UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLOIDAL GOLD; COPOLYMER; DRUG CARRIER; DYSTROPHIN; EXON SKIPPING OLIGONUCLEOTIDE; MACROGOL; OLIGONUCLEOTIDE; POLYETHYLENEIMINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DUCHENNE MUSCULAR DYSTROPHY; GENE; GENETIC TRANSFECTION; IN VIVO STUDY; MALE; MDX GENE; MOUSE; MUSCLE TISSUE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TIBIALIS ANTERIOR MUSCLE; TISSUE DISTRIBUTION; WESTERN BLOTTING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DRUG CARRIERS; DYSTROPHIN; EXONS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; MALE; MICE; MICE, INBRED MDX; MUSCLE FIBERS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; TRANSFECTION;

MUS;

EID: 50649089185     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.129     Document Type: Article

References (51)

1. Aartsma-Rus, A., Bremmer-Bout, M., Janson, A.A., den Dunnen, J.T., van Ommen, G.J., and van Deutekom, J.C. (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12(Suppl. 1), S71-S77.
2. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., Bremmer-Bout, M., den Dunnen, J.T., Baas, F., van Ommen, G.J., and van Deutekom, J.C. (2003). Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12, 907-914.
3. Aartsma-Rus, A., Janson, A.A., Kaman, W.E., Bremmer-Bout, M., van Ommen, G.J., den Dunnen, J.T., and van Deutekom, J.C. (2004a). Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am. J. Hum. Genet. 74, 83-92.
4. Aartsma-Rus, A., Kaman, W.E., Bremmer-Bout, M., Janson, A.A., den Dunnen, J.T., van Ommen, G.J., and van Deutekom, J.C. (2004b). Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 11, 1391-1398.
5. Abes, R., Arzumanov, A.A., Moulton, H.M., Abes, S., Ivanova, G.D., Iversen, P.L., Gait, M.J., and Lebleu, B. (2007). Cell-penetrating-peptide-based delivery of oligonucleotides: An overview. Biochem. Soc. Trans. 35, 775-779.
6. Adams, A.M., Harding, P.L., Iversen, P.L., Coleman, C., Fletcher, S., and Wilton, S.D. (2007). Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. BMC Mol. Biol. 8, 57.
7. Akinc, A., Thomas, M., Klibanov, A.M., and Langer, R. (2005). Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7, 657-663.
8. Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S.D., Partridge, T.A., and Lu, Q.L. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175-177.
9. Bieber, T., Meissner, W., Kostin, S., Niemann, A., and Elsasser, H.P. (2002). Intracellular route and transcriptional competence of polyethylenimine-DNA complexes. J. Control. Release 82, 441-454.
10. Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., and Behr, J.P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 92, 7297-7301.
11. Bremmer-Bout, M., Aartsma-Rus, A., de Meijer, E.J., Kaman, W.E., Janson, A.A., Vossen, R.H., van Ommen, G.J., den Dunnen, J.T., and van Deutekom, J.C. (2004). Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. Mol. Ther. 10, 232-240.
12. Fischer, D., Osburg, B., Petersen, H., Kissel, T., and Bickel, U. (2004). Effect of poly(ethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug Metab. Dispos. 32, 983-992.
13. Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., and Wilton, S.D. (2005). Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J. Gene Med. 8, 207-216.
14. Fletcher, S., Honeyman, K., Fall, A.M., Harding, P.L., Johnsen, R.D., Steinhaus, J.P., Moulton, H.M., Iversen, P.L., and Wilton, S.D. (2007). Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 15, 1587-1592.
15. Forrest, M.L., Meister, G.E., Koerber, J.T., and Pack, D.W. (2004). Partial acetylation of polyethylenimine enhances in vitro gene delivery. Pharm. Res. 21, 365-371.
16. Gait, M.J. (2003). Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Cell. Mol. Life Sci. 60, 844-853.
17. Garcia-Blanco, M.A., Baraniak A.P., and Lasda, E.L. (2004). Alternative splicing in disease and therapy. Nat. Biotechnol. 22, 535-546.
18. Gebski, B.L., Mann, C.J., Fletcher, S., and Wilton, S.D. (2003). Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 12, 1801-1811.
19. Glodde, M., Sirsi, S.R., and Lutz, G.J. (2006). Physiochemical properties of low and high molecular weight PEG-grafted poly(ethylene imine) copolymers and their complexes with oligonucleotides. Biomacromolecules 7, 347-356.
20. Godbey, W.T., Wu, K.K., and Mikos, A.G. (1999). Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc. Natl. Acad. Sci. U.S.A. 96, 5177-5181.
21. Hainfeld, J.F., and Powell, R.D. (2000). New frontiers in gold labeling. J. Histochem. Cytochem. 48, 471-480.
22. Ho, A., Schwarze, S.R., Mermelstein, S.J., Waksman, G., and Dowdy, S.F. (2001). Synthetic protein transduction domains: Enhanced transduction potential in vitro and in vivo. Cancer Res. 61, 474-477.
23. Kaisto, T., Rahkila, P., Marjomaki, V., Parton, R.G., and Metsikko, K. (1999). Endocytosis in skeletal muscle fibers. Exp. Cell Res. 253, 551-560.
24. Kichler, A. (2004). Gene transfer with modified polyethylenimines. J. Gene Med. 6(Suppl. 1), S3-S10.
25. Kole, R., Williams T., and Cohen, L. (2004). RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim. Pol. 51, 373-378.
26. Kunath, K., von Harpe, A., Fischer, D., and Kissel, T. (2003). Galactose-PEI-DNA complexes for targeted gene delivery: Degree of substitution affects complex size and transfection efficiency. J. Control. Release 88, 159-172.
27. Kurreck, J. (2003). Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644.
28. Kursa, M., Walker, G.F., Roessler, V., Ogris, M., Roedl, W., Kircheis, R., and Wagner, E. (2003). Novel shielded transferrin -polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug. Chem. 14, 222-231.
29. Lee, K.M., Kim, I.S., Lee, Y.B., Shin, S.C., Lee, K.C., and Oh, I.J. (2005). Evaluation of transferrin-polyethylenimine conjugate for targeted gene delivery. Arch. Pharm. Res. 28, 722-729.
30. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A., and Wilton, S.D. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9, 1009-1014.
31. Lu, Q.L., Rabinowitz, A., Chen, Y.C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., and Partridge, T. (2005). From the cover: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U.S.A. 102, 198-203.
32. Mann, C.J., Honeyman, K., McClorey, G., Fletcher, S., and Wilton, S.D. (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. 4, 644-654.
33. McClorey, G., Moulton, H.M., Iversen, P.L., Fletcher, S., and Wilton, S.D. (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther. 13, 1373-1381.
34. Moulton, H.M., Fletcher, S., Neuman, B.W., McClorey, G., Stein, D.A., Abes, S., Wilton, S.D., Buchmeier, M.J., Lebleu, B., and Iversen, P.L. (2007). Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem. Soc. Trans. 35, 826-828.
35. Ogris, M., Brunner, S., Schuller, S., Kircheis, R., and Wagner, E. (1999). PEGylated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595-605.
36. Ogris, M., Steinlein, P., Carotta, S., Brunner, S., and Wagner, E. (2001). DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSci. 3, E21.
37. Ogris, M., Walker, G., Blessing, T., Kircheis, R., Wolschek, M., and Wagner, E. (2003). Tumor-targeted gene therapy: Strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/ DNA complexes. J. Control. Release 91, 173-181.
38. Petersen, H., Fechner, P.M., Fischer, D., and Kissel, T. (2002a). Synthesis, characterization, and biocompatibility of polyethylenimine-graft- poly(ethylene glycol) block copolymers. Macromolecules 35, 6867-6874.
39. Petersen, H., Fechner, P.M., Martin, A.L., Kunath, K., Stolnik, S., Roberts, C.J., Fischer, D., Davies, M.C., and Kissel, T. (2002b). Polyethylenimine-graft-poly(ethylene glycol) copolymers: Influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug. Chem. 13, 845-854.
40. Rasband, W.S. (1997-2007). ImageJ (National Institutes of Health, Bethesda, MD). Available at http://rsb.info.nih.gov/ij/ (accessed June 2008).
41. Shi, L., Tang, G.P., Gao, S.J., Ma, Y.X., Liu, B.H., Li, Y., Zeng, J.M., Ng, Y.K., Leong, K.W., and Wang, S. (2003). Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther. 10, 1179-1188.
42. Shukla, R., Bansal, V., Chaudhary, M., Basu, A., Bhonde, R.R., and Sastry, M. (2005). Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: A microscopic overview. Langmuir 21, 10644-10654.
43. Sonawane, N.D., Szoka, F.C., Jr., and Verkman, A.S. (2003). Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278, 44826-44831.
44. Suh, J., Wirtz, D., and Hanes, J. (2003). Efficient active transport of gene nanocarriers to the cell nucleus. Proc. Natl. Acad. Sci. U.S.A. 100, 3878-3882.
45. Sung, S.J., Min, S.H., Cho, K.Y., Lee, S., Min, Y.J., Yeom, Y.I., and Park, J.K. (2003). Effect of polyethylene glycol on gene delivery of polyethylenimine. Biol. Pharm. Bull. 26, 492-500.
46. Thomas, M., and Klibanov, A.M. (2002). Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 99, 14640-14645.
47. Thomas, M., and Klibanov, A.M. (2003a). Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 100, 9138-9143.
48. Thomas, M., and Klibanov, A.M. (2003b). Non-viral gene therapy: Polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 62, 27-34.
49. Toro, A., and Grunebaum, E. (2006). TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J. Clin. Invest 116, 2717-2726.
50. Williams, J.H., Sirsi, S.R., Latta, D., and Lutz, G.J. (2006). Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers. Mol. Ther. 14, 88-96.
51. Williams, J.H., Schray, R.C., Sirsi, S.R., and Lutz, G.J. (2008). Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. BMC Biotechnol. 8, 35.